A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)-Reference-Cited by-同舟云学术

A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

Published:2018-03 Issue:3 Volume:32 Page:289-301
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Wigal Tim L.,Newcorn Jeffrey H.^ORCID,Handal Nelson,Wigal Sharon B.,Mulligan Ioulietta,Schmith Virginia^ORCID,Konofal Eric^ORCID

Funder

NLS-1 Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

http://link.springer.com/article/10.1007/s40263-018-0503-y/fulltext.html

Reference31 articles.

1. Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014;126(5):64–81.

2. Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology. 2011;36(1):207–26.

3. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–63.

4. Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Advances in understanding and treating ADHD. BMC Med. 2011;10(9):72.

5. Nittur N, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VC, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med. 2013;14(1):30–6.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults;Neuroscience & Biobehavioral Reviews;2024-08

2. From past to future: 50 years of pharmacological interventions to treat narcolepsy;Pharmacology Biochemistry and Behavior;2024-08

3. Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents;Expert Review of Neurotherapeutics;2024-03-19

4. NLS-3 (Levophacetoperane or (R,R) Phacetoperane): A Reverse Ester of Methylphenidate: A Literature Review;Current Medicinal Chemistry;2024-03

5. An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy;Journal of Pharmacokinetics and Pharmacodynamics;2023-03-17